Literature DB >> 26408706

Non-covalent Nanocomplexes of Folic Acid and Reducible Polyethylenimine for Survivin siRNA Delivery.

Bin Zheng1, Shuang Yang1, Mengqiao Wang1, Xuewei Yang1, Lirong Teng1, Jing Xie1, Lesheng Teng2, Robert J Lee3.   

Abstract

BACKGROUND/AIM: Efficient delivery of siRNA is critical for its therapeutic applications. This study was aimed at the design, synthesis and evaluation of a novel delivery system based on non-covalent complexes of folic acid (FA) and a reducible polyethylenimine (PEI) derivative, PEI-SS.
MATERIALS AND METHODS: PEI-SS was synthesized by crosslinking low-molecular weight PEI using a reducible crosslinking agent. PEI-SS-siRNA complexes were synthesized and further combined with FA to form FA/PEI-SS-siRNA nanocomplexes. These were then evaluated in two tumor cell lines for survivin siRNA delivery.
RESULTS: FA/PEI-SS-siRNA complexes were taken-up by both HeLa and A549 cells efficiently. This was not affected by the expression level of the folate receptor on the tumor cell surface. Furthermore, FA/PEI-SS-siRNA complexes reduced the level of survivin expression in both cell lines.
CONCLUSION: FA/PEI-SS is a potent siRNA carrier that warrants further evaluation. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Polyethylenimine; cancer; drug delivery; folate receptor; nanoparticle; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26408706

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  DNA Tetrahedron Delivery Enhances Doxorubicin-Induced Apoptosis of HT-29 Colon Cancer Cells.

Authors:  Guiyu Zhang; Zhiyong Zhang; Junen Yang
Journal:  Nanoscale Res Lett       Date:  2017-08-15       Impact factor: 4.703

2.  Targeted delivery and enhanced gene-silencing activity of centrally modified folic acid-siRNA conjugates.

Authors:  Lidya Salim; Golam Islam; Jean-Paul Desaulniers
Journal:  Nucleic Acids Res       Date:  2020-01-10       Impact factor: 16.971

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.